RajeevSaggarMD

Pulmonology • Phoenix, AZ

Critical Care Medicine, Pleural Disease

Physician

Join to view full profile

Dr. Saggar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Saggar's full profile

Already have an account?

Office
755 E McDowell Rd
3rd Floor
Phoenix, AZ 85006
Phone+1 602-255-7600

Fax+1 602-839-7663

Education & Training

University of California (Irvine)Fellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
University of California (Irvine)Residency, Internal Medicine, 2002 - 2005
University of California, Irvine, School of MedicineClass of 2002

Certifications & Licensure

AZ State Medical License 2011 - 2026
CA State Medical License 2004 - 2026

Clinical Trials

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension Start of enrollment: 2011 Jan 01
Completed
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Start of enrollment: 2009 Mar 01
Completed
Phase 4
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis Start of enrollment: 2016 Feb 01
Withdrawn
Phase 2
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.
John Belperio, Tuan Nguyen, David A Lombardi, Maxim Bogus, Valentyn Moskalenko
BMJ Open Respiratory Research. 2023-07-01
33 citations
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Dave Singh, Maxim Bogus, Valentyn Moskalenko, RW Lord, Edmund J. Moran
The European Respiratory Journal. 2021-07-01
4 citations
Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort study.
Rajeev Saggar, Paresh C. Giri, Chunqin Deng, Dana Johnson, Mary K McCloy
Pulmonary Circulation. 2021-05-02